title: The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy.
abstract: We performed a dose-escalation study of bendamustine in 31 patients with multiple myeloma that had progressed after high-dose chemotherapy. Bendamustine 100 mg/m2 on days 1 and 2 per cycle was found to be the maximal tolerated dose. The overall response rate was 55% with a median progression-free survival of 26 (0-61) weeks. Toxicity was mild and mainly hematologic.
authors.forename: Stefan
authors.initials: S
authors.lastname: Knop
authors.forename: Christian
authors.initials: C
authors.lastname: Straka
authors.forename: Michael
authors.initials: M
authors.lastname: Haen
authors.forename: Renate
authors.initials: R
authors.lastname: Schwedes
authors.forename: Holger
authors.initials: H
authors.lastname: Hebart
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000069461:Bendamustine Hydrochloride; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000453:epidemiology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000453:epidemiology; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride